-
Sector Analysis
New![]()
Multiple Myeloma Epidemiology Analysis and Forecast to 2032
Multiple Myeloma Vaccines Report Overview In the 8MM, there were 80,305 diagnosed incident cases of multiple myeloma vaccines in 2022. The diagnosed incident cases of multiple myeloma vaccines are expected to register an AGR of more than 1% during 2022-2032. Multiple myeloma (MM) is a hematologic cancer that forms in a type of white blood cell called plasma cells. Normal plasma cells help fight infections by making antibodies that recognize and attack germs, but MM causes cancer cells to accumulate...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nk Cell Multiple Myeloma in Multiple Myeloma (Kahler Disease)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Nk Cell Multiple Myeloma in Multiple Myeloma (Kahler Disease) Drug Details:Cell therapy is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CAR-T Cell Multiple Myeloma in Multiple Myeloma (Kahler Disease)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Car-T Cell Multiple Myeloma in Multiple Myeloma (Kahler Disease) Drug Details:Gene-modified cell therapy is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target Bcma For Multiple Myeloma in Multiple Myeloma (Kahler Disease)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Gene Therapy To Target Bcma For Multiple Myeloma in Multiple Myeloma (Kahler Disease)Drug Details:Gene therapy is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target MAGE-A1 For Multiple Myeloma in Refractory Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Gene Therapy To Target MAGE-A1 For Multiple Myeloma in Refractory Multiple Myeloma Drug Details: Gene...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target Bcma And Cd38 For Relapsed And Refractorymultiple Myeloma in Relapsed Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Gene Therapy To Target Bcma And Cd38 For Relapsed And Refractorymultiple Myeloma in Relapsed Multiple MyelomaDrug...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target Bcma And Cd38 For Relapsed And Refractorymultiple Myeloma in Refractory Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Gene Therapy To Target Bcma And Cd38 For Relapsed And Refractorymultiple Myeloma in Refractory Multiple MyelomaDrug...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target Bcma And Cd38 For Relapsed And Refractorymultiple Myeloma in Multiple Myeloma (Kahler Disease)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Gene Therapy To Target Bcma And Cd38 For Relapsed And Refractorymultiple Myeloma in Multiple Myeloma (Kahler...
-
New
![]()
Likelihood of Approval and Phase Transition Success Rate Model – Subasumstat in Relapsed Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Subasumstat in Relapsed Multiple Myeloma Drug Details: TAK-981 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Atezolizumab in Relapsed Multiple Myeloma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Atezolizumab in Relapsed Multiple Myeloma Drug Details: Atezolizumab (Tecentriq) is an antineoplastic agent. It is...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.